CHARLOTTE -- Chelsea Therapeutics is in the middle of second-stage
clinical testing on a drug to treat rheumatoid arthritis. The
three-month test of CH-1504 is scheduled to end in April. Chelsea
believes its drug is as effective as existing treatments and has fewer
side effects.
For a daily roundup of business news in the Charlotte region, log
onto www.BusinessNC.com/Charlotte.
COPYRIGHT 2008 Business North
Carolina Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.
Browse by Journal Name: